At a glance
| US brand | Mimrylo |
|---|---|
| FDA approval | August 28, 2026 |
| Approved population | Adults with PV-associated erythrocytosis |
| Target | Ferroportin |
| Hormone mimicked | Hepcidin |
| Key monitoring | Hematocrit, hemoglobin, and platelets |
Overview
Polycythemia vera is a myeloproliferative disease in which excessive red-cell production can require repeated therapeutic phlebotomy and other treatment. Rusfertide targets iron regulation rather than directly eliminating the underlying abnormal cell clone. By mimicking hepcidin, it reduces the iron supply available for erythropoiesis and helps control hematocrit. Earlier REViVE findings led to the phase 3 VERIFY program and US approval of Mimrylo on August 28, 2026. Its approved indication is erythrocytosis in adults with polycythemia vera. This should not be broadened to general blood donation replacement, every cause of high hematocrit, iron overload, or treatment of anemia.
How it works
Rusfertide inhibits ferroportin, the transporter that moves iron from cells into circulation, reproducing a central action of endogenous hepcidin. Reduced iron availability to the marrow limits red-cell production and lowers hematocrit. This is iron redistribution and restriction of erythropoiesis, not destruction of mature red cells. The mechanism also explains why blood counts and anemia require monitoring and why the drug does not itself eradicate the PV clone.
From REViVE to VERIFY
REViVE showed improved hematocrit control and reduced phlebotomy requirements, including a randomized withdrawal comparison. The phase 3 VERIFY study evaluated rusfertide added to ongoing standard care in adults requiring repeated phlebotomy. The approved label describes the controlled results supporting use; improvement in these endpoints is not the same as proof of curing PV.
A current approval, not just a trial candidate
FDA approved Mimrylo for erythrocytosis in adults with polycythemia vera on August 28, 2026. Earlier references correctly described development at their publication dates but are outdated if presented as current status. The indication remains specific to PV-related erythrocytosis rather than all disorders of iron or red-cell production.
Platelets and anemia require attention
Current labeling warns about new or worsening thrombocytosis and calls for blood-count monitoring. Injection-site reactions and anemia were common adverse reactions in the clinical program. Embryo-fetal toxicity is another warning. Hematocrit improvement therefore needs to be considered alongside platelets, symptoms, other PV therapy, and the overall treatment plan.
Supporting sources [1]
Does it eliminate the need for other PV care?
Not necessarily. The pivotal trial allowed ongoing standard treatment, and rusfertide targets erythrocytosis through iron regulation rather than removing the underlying neoplastic clone. A reduction in phlebotomy burden does not establish that every patient can stop cytoreductive therapy or that long-term thrombotic risk has been eliminated.
Reading this profile
Jurisdiction: United States; indications and availability vary by formulation and country.. Molecular class: Synthetic hepcidin-mimetic peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Mimrylo — current US prescribing information ↗Regulatory source · Checked 2026-10-27
- Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera. ↗Original research · Checked 2026-10-27
- FDA Mimrylo approval letter (2026) ↗Regulatory source · Checked 2026-10-27